Share on StockTwits

USANA Health Sciences (NASDAQ:USNA) Director Myron W. Wentz sold 7,000 shares of USANA Health Sciences stock on the open market in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $74.69, for a total value of $522,830.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

USANA Health Sciences (NASDAQ:USNA) traded up 0.85% on Friday, hitting $76.08. 136,066 shares of the company’s stock traded hands. USANA Health Sciences has a 52 week low of $55.01 and a 52 week high of $92.00. The stock has a 50-day moving average of $72.34 and a 200-day moving average of $72.23. The company has a market cap of $1.059 billion and a P/E ratio of 13.90.

USANA Health Sciences (NASDAQ:USNA) last announced its earnings results on Tuesday, April 29th. The company reported $1.15 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.30 by $0.15. The company had revenue of $182.40 million for the quarter, compared to the consensus estimate of $185.85 million. During the same quarter in the prior year, the company posted $1.28 earnings per share. The company’s quarterly revenue was up 7.9% on a year-over-year basis. On average, analysts predict that USANA Health Sciences will post $5.66 earnings per share for the current fiscal year.

Separately, analysts at Zacks downgraded shares of USANA Health Sciences from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 8th. They now have a $79.50 price target on the stock. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $79.38.

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.